[go: up one dir, main page]

LT1976880T - Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea - Google Patents

Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea

Info

Publication number
LT1976880T
LT1976880T LTEP06841112.3T LT06841112T LT1976880T LT 1976880 T LT1976880 T LT 1976880T LT 06841112 T LT06841112 T LT 06841112T LT 1976880 T LT1976880 T LT 1976880T
Authority
LT
Lithuania
Prior art keywords
resistance
pharmaceutical compositions
soluble cea
cea
soluble
Prior art date
Application number
LTEP06841112.3T
Other languages
English (en)
Inventor
Ralf Lutterbüse
Petra Mayer
Evelyne Schaller
Doris Rau
Susanne Mangold
Peter Kufer
Alexander Murr
Monika Wissinger
Tobias Raum
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Publication of LT1976880T publication Critical patent/LT1976880T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
LTEP06841112.3T 2005-12-21 2006-12-21 Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea LT1976880T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75196305P 2005-12-21 2005-12-21
EP05028064 2005-12-21
US78086106P 2006-03-10 2006-03-10
PCT/EP2006/012425 WO2007071426A1 (en) 2005-12-21 2006-12-21 Pharmaceutical compositions with resistance to soluble cea

Publications (1)

Publication Number Publication Date
LT1976880T true LT1976880T (lt) 2016-10-10

Family

ID=40413962

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP06841112.3T LT1976880T (lt) 2005-12-21 2006-12-21 Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea

Country Status (24)

Country Link
US (3) US8394926B2 (lt)
EP (2) EP1976880B1 (lt)
JP (2) JP5399712B2 (lt)
KR (1) KR101287777B1 (lt)
CN (1) CN101370827B (lt)
AU (1) AU2006328886C1 (lt)
BR (1) BRPI0620632A2 (lt)
CA (1) CA2633766C (lt)
CY (1) CY1118053T1 (lt)
DK (1) DK1976880T3 (lt)
ES (1) ES2595091T3 (lt)
HR (1) HRP20161216T1 (lt)
HU (1) HUE031151T2 (lt)
IL (1) IL192277A (lt)
LT (1) LT1976880T (lt)
ME (1) ME02581B (lt)
NZ (1) NZ569204A (lt)
PL (1) PL1976880T3 (lt)
PT (1) PT1976880T (lt)
RS (1) RS55181B1 (lt)
RU (2) RU2426743C2 (lt)
SG (1) SG193141A1 (lt)
WO (1) WO2007071426A1 (lt)
ZA (1) ZA200805400B (lt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2574953A1 (en) 2004-07-26 2006-02-09 Dow Global Technolgies Inc. Process for improved protein expression by strain engineering
US20090226444A1 (en) * 2005-12-21 2009-09-10 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
US8394926B2 (en) * 2005-12-21 2013-03-12 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA
CA2685326A1 (en) 2007-04-27 2008-11-06 Dow Global Technologies Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9308257B2 (en) * 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
IN2012DN01663A (lt) 2009-09-16 2015-06-05 Immunomedics Inc
US20130035249A1 (en) * 2009-12-01 2013-02-07 Medimmune, Llc Methods and compositions for detecting and treating cea-expressing cancers
PT3604339T (pt) 2011-01-14 2021-04-13 Univ California Anticorpos terapêuticos contra a proteína ror-1 e métodos para utilização dos mesmos
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
WO2013054320A1 (en) * 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013162748A1 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP3586874A1 (en) 2012-08-14 2020-01-01 IBC Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
NZ746691A (en) 2012-11-13 2020-08-28 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
TWI664192B (zh) 2012-11-20 2019-07-01 法商賽諾菲公司 抗ｃｅａｃａｍ５抗體及其用途
MX2015010350A (es) 2013-02-26 2015-10-29 Roche Glycart Ag Moleculas de union a antigeno biespecificas que activan la celula t.
EP2961771B1 (en) * 2013-02-26 2020-01-01 Roche Glycart AG Bispecific t cell activating antigen binding molecules specific to cd3 and cea
US20160122436A1 (en) 2013-03-15 2016-05-05 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
CN106573977B (zh) 2014-04-27 2020-08-07 菲姆威有限公司 针对ceacam1的人源化抗体
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
PE20170286A1 (es) 2014-07-01 2017-03-30 Pfizer Diacuerpos heterodimericos biespecificos y sus usos
SG11201705988UA (en) 2015-02-24 2017-08-30 Bioatla Llc Conditionally active biological proteins
CN106432502B (zh) * 2015-08-10 2020-10-27 中山大学 用于治疗cea阳性表达肿瘤的双特异纳米抗体
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN107849137B (zh) 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗ceaxcd3 t细胞活化性抗原结合分子
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
EP3400246B1 (en) 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
HRP20250113T1 (hr) 2016-06-02 2025-03-28 Immunocore Limited Režim doziranja za gp100-specifični tcr - anti-cd3 scfv fuzijski protein
CN107663240B (zh) 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
CN117752798A (zh) 2016-12-19 2024-03-26 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
MA47200A (fr) 2017-01-03 2019-11-13 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb
CN107056952A (zh) * 2017-05-10 2017-08-18 常州市第人民医院 Cea.car‑t及其制备与应用
CN107058234B (zh) * 2017-05-12 2019-09-13 常州市第一人民医院 Car.il-33-t及其制备与应用
CN113896797B (zh) 2017-08-01 2023-05-09 Ab工作室有限公司 双特异性抗体及其用途
MX2020004573A (es) 2017-11-01 2020-09-25 Hoffmann La Roche Terapia de combinacion con agonistas de ox40 dirigidos.
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
JP7403479B2 (ja) 2018-06-03 2023-12-22 ランカプ バイオ ベータ リミテッド Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体
WO2020007817A1 (en) 2018-07-04 2020-01-09 F. Hoffmann-La Roche Ag Novel bispecific agonistic 4-1bb antigen binding molecules
US11608376B2 (en) 2018-12-21 2023-03-21 Hoffmann-La Roche Inc. Tumor-targeted agonistic CD28 antigen binding molecules
US12463463B2 (en) 2019-01-28 2025-11-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
BR112021014636A2 (pt) 2019-02-07 2021-12-21 Sanofi Sa Uso de imunoconjugados anti-ceacam5 para tratamento de câncer de pulmão
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
US20200390899A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
CN114531878A (zh) * 2019-06-27 2022-05-24 豪夫迈·罗氏有限公司 新颖icos抗体及包含它们的肿瘤靶向抗原结合分子
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
CN114630684A (zh) 2019-09-03 2022-06-14 博尔特生物治疗药物有限公司 氨基喹啉化合物、免疫缀合物及其用途
HUE067160T2 (hu) 2019-09-18 2024-10-28 Lamkap Bio Alpha AG Bispecifikus antitestek CEACAM5 és CD3 ellen
EP4038053A1 (en) 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
TWI857167B (zh) 2019-10-25 2024-10-01 美商博特生物治療公司 噻吩并氮呯免疫結合物及其用途
WO2021098822A1 (zh) * 2019-11-21 2021-05-27 江苏恒瑞医药股份有限公司 一种双特异性抗体
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
CA3182445A1 (en) 2020-06-11 2021-12-16 Francisco Leon Methods and compositions for preventing type 1 diabetes
WO2022036101A1 (en) 2020-08-13 2022-02-17 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
JP2024501453A (ja) 2020-12-11 2024-01-12 ボルト バイオセラピューティクス、インコーポレーテッド 抗ｃｅａイムノコンジュゲート、及びそれらの使用
ES2967381T3 (es) 2020-12-18 2024-04-30 Lamkap Bio Beta Ag Anticuerpos biespecíficos contra CEACAM5 y CD47
CA3212907A1 (en) 2021-03-26 2022-09-29 Gary Brandt 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
JP2024511088A (ja) 2021-03-26 2024-03-12 ボルト バイオセラピューティクス、インコーポレーテッド ２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
MX2024011519A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
CN119998319A (zh) 2022-06-16 2025-05-13 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗
WO2024192308A2 (en) 2023-03-14 2024-09-19 Xencor, Inc. Anti-cd28 compositions
AU2024311339A1 (en) 2023-06-21 2026-01-08 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
KR100237968B1 (ko) 1990-12-05 2000-01-15 한센 핀 베네드 변화된 에피토프를 지닌 단백질 및 그 제조방법
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
MXPA03007323A (es) 2001-02-19 2003-12-12 Merck Patent Gmbh Proteinas artificiales con inmunogenicidad reducida.
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7820166B2 (en) * 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
NZ546173A (en) 2003-10-16 2009-04-30 Micromet Ag Multispecific deimmunized CD3-binders
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US8394926B2 (en) 2005-12-21 2013-03-12 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA
US20090226444A1 (en) * 2005-12-21 2009-09-10 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea

Also Published As

Publication number Publication date
EP1976880B1 (en) 2016-07-06
WO2007071426A1 (en) 2007-06-28
HUE031151T2 (en) 2017-06-28
BRPI0620632A2 (pt) 2011-12-20
US20090226432A1 (en) 2009-09-10
RU2008129787A (ru) 2010-01-27
SG193141A1 (en) 2013-09-30
JP2009520734A (ja) 2009-05-28
NZ569204A (en) 2012-03-30
JP5399712B2 (ja) 2014-01-29
ES2595091T3 (es) 2016-12-27
RU2010148652A (ru) 2012-06-10
AU2006328886B2 (en) 2011-04-14
AU2006328886C1 (en) 2011-11-17
IL192277A (en) 2016-08-31
EP1976880A1 (en) 2008-10-08
PL1976880T3 (pl) 2017-01-31
PT1976880T (pt) 2016-09-28
KR20080079330A (ko) 2008-08-29
ME02581B (me) 2017-06-20
HRP20161216T1 (hr) 2016-11-18
US9695250B2 (en) 2017-07-04
RU2426743C2 (ru) 2011-08-20
CN101370827B (zh) 2015-10-14
RS55181B1 (sr) 2017-01-31
DK1976880T3 (en) 2016-09-26
RU2573893C2 (ru) 2016-01-27
JP2013056885A (ja) 2013-03-28
IL192277A0 (en) 2008-12-29
CA2633766A1 (en) 2007-06-28
HK1115890A1 (zh) 2008-12-12
US8394926B2 (en) 2013-03-12
EP2527370A1 (en) 2012-11-28
CY1118053T1 (el) 2017-06-28
AU2006328886A1 (en) 2007-06-28
CA2633766C (en) 2016-06-28
KR101287777B1 (ko) 2013-07-23
US20130273050A1 (en) 2013-10-17
ZA200805400B (en) 2009-09-30
US20170137538A1 (en) 2017-05-18
CN101370827A (zh) 2009-02-18
US9982063B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
IL192277A0 (en) Pharmaceutical compositions with resistance to soluble cea
IL283205A (en) Attached medicinal substance that binds to cells, preparations containing them and their uses
IL289165A (en) Compounds with anticancer activity
HRP20181837T1 (hr) Farmaceutski pripravci koji sadrže zeljezov oksi-hidroksid
SI1984009T1 (sl) Farmacevtski sestavki z izboljĺ ano stabilnostjo
GB0603464D0 (en) Improvements in & relating to external neurostimulation
ZA200807721B (en) Anti-cancer pharmaceutical composition
IL192911A0 (en) Compositions containing microalgae-derived polysaccharides and methods for the preparation thereof
IL200251A0 (en) Compositions and methods to prevent cancer with cupredoxins
IL193706A0 (en) Photoactive compounds and compositions and uses thereof
ZA200900199B (en) Hard alloys with dry composition
IL197602A0 (en) Compositions and methods to prevent cancer with cupredoxins
IL205966A0 (en) Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof
GB0617191D0 (en) Improvements in pharmaceutical compositions
IL186337A0 (en) Stannsoporfin compositions and administration
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
GB0715428D0 (en) Compositions and uses thereof
IL208567A0 (en) Oligomer-aryloxy-substituted propanamine conjugates, compositions comprising the same and uses thereof
GB0701170D0 (en) Compositions and uses thereof
GB0701171D0 (en) Compositions and uses thereof
IL247297A0 (en) Medicinal compounds with resistance to soluble cea
GB0725264D0 (en) Compositions and uses thereof
GB0517043D0 (en) Improvements in pharmaceutical compositions
GB0718825D0 (en) Salaris and tulearins and compositions and uses thereof
GB0614848D0 (en) Improvements in pharmaceutical compositions